Aytu BioPharma (AYTU) Fiscal Q4 2026 Earnings Call: EXXUA Growth and FY2027 Outlook
Source Tradingkey
Key Takeaways
- Aytu BioPharma reported fiscal Q4 2026 net revenue of $16.1 million, up 6% year over year and from $12.4 million in fiscal Q3. Full-year net revenue was $57.6 million.
- EXXUA generated $3.9 million of Q4 net revenue, up from $2.4 million in Q3. Quarterly prescriptions rose to 3,323 from 1,398, while 4,599 units were shipped.
- The company returned to positive quarterly adjusted EBITDA of $0.5 million, versus a $2.8 million loss in Q3. Q4 net loss narrowed to $0.1 million.
- Cash remained relatively stable at $26.3 million as of June 30, 2026, despite debt reduction. Aytu generated $3.3 million of operating cash flow for fiscal 2026 and subsequently repaid the remaining revolving credit balance.
- Management expects fiscal 2027 GAAP operating expenses of $49 million to $54 million and cash-based operating expenses of $45 million to $49 million. It expects the six months ending June 30, 2027, to generate positive adjusted EBITDA.
- EXXUA prescriptions continued rising after quarter-end, reaching 1,377 in July, 1,408 in August, and a weekly record of 394 for the week ended September 4.
Key Financial Data
| Metric | Fiscal Q4 2026 | Comparison / context |
|---|---|---|
| Net revenue | $16.1 million | Up 6% from $15.1 million a year earlier; Q3 was $12.4 million |
| EXXUA net revenue | $3.9 million | Up from $2.4 million in Q3 |
| ADHD portfolio revenue | $10.4 million | $13.1 million a year earlier; $9.1 million in Q3 |
| Pediatrics revenue | $1.8 million | $2.0 million a year earlier; $0.9 million in Q3 |
| Gross profit | $10.4 million | $10.3 million a year earlier |
| Gross margin | Approximately 65% | 68% a year earlier and 61% in Q3 |
| Operating expenses | $11.2 million | $17.9 million a year earlier, including an $8.3 million prior-year impairment charge |
| Net loss | $0.1 million | $19.8 million loss a year earlier |
| Adjusted EBITDA | $0.5 million | $2.0 million a year earlier; negative $2.8 million in Q3 |
| Cash and cash equivalents | $26.3 million | $26.7 million at March 31 and $31.0 million at fiscal 2025 year-end |
Disclaimer: The content available on Mitrade Insights is provided for informational and marketing purposes only. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research
Nothing in this material constitutes investment advice, personal recommendation, investment research, an offer, or a solicitation to buy or sell any financial instrument. The content has been prepared without consideration of your individual investment objectives, financial situation, or needs, and should not be treated as such.
Past performance is not a reliable indicator of future performance and/or results. Forward-looking scenarios or forecasts are not a guarantee of future performance. Actual results may differ materially from those anticipated.
Mitrade makes no representation or warranty as to the accuracy or completeness of the information provided and accepts no liability for any loss arising from reliance on such information.
Nothing in this material constitutes investment advice, personal recommendation, investment research, an offer, or a solicitation to buy or sell any financial instrument. The content has been prepared without consideration of your individual investment objectives, financial situation, or needs, and should not be treated as such.
Past performance is not a reliable indicator of future performance and/or results. Forward-looking scenarios or forecasts are not a guarantee of future performance. Actual results may differ materially from those anticipated.
Mitrade makes no representation or warranty as to the accuracy or completeness of the information provided and accepts no liability for any loss arising from reliance on such information.
Recommended Articles
West Texas Intermediate (WTI), the US crude oil benchmark, is trading around $63.80 during the early Asian trading hours on Tuesday. The WTI price falls as concerns about supply disruptions in the Middle East have faded.
Commerzbank’s Michael Pfister discusses how US allies in Middle East and Asia are seeking Dollar swap lines as conflicts curb energy exports and tourism.
Japan's Nikkei closes at record high as tech earnings overshadow Mideast concernsBy Rocky Swift TOKYO, April 24 (Reuters) - Japan's Nikkei set a closing record high on Friday, capping a third consecutive weekly gain, as enthusiasm over technology sector earnings offset uncertainty over a potential peace deal in the Middle East.The benchmark Nikkei 225 Index .N225 rose 0.9...
By Rocky Swift TOKYO, April 24 (Reuters) - Japan's Nikkei set a closing record high on Friday, capping a third consecutive weekly gain, as enthusiasm over technology sector earnings offset uncertainty over a potential peace deal in the Middle East.The benchmark Nikkei 225 Index .N225 rose 0.9...
Bitcoin (BTC) slides slightly but holds most of the recent gains, reclaiming the 50-day Exponential Moving Average (EMA) at $64,300 at the time of writing on Tuesday after rising 2.5% the previous day.
WTI Price Forecast: Climbs above $86.00 as 100-day SMA breakout comes into playWest Texas Intermediate (WTI) – the benchmark US Crude Oil price – attracts buyers for the second straight day on Tuesday as escalating US-Iran tensions and the standoff over the Strait of Hormuz continue to fuel supply concerns.
West Texas Intermediate (WTI) – the benchmark US Crude Oil price – attracts buyers for the second straight day on Tuesday as escalating US-Iran tensions and the standoff over the Strait of Hormuz continue to fuel supply concerns.
